A study suggested that intravenous injection of the P2X3 antagonist AF-353 decreased the frequency of sensory field potentials evoked by activation of bladder noxious pathways and decreased the frequency of nonvoiding contractions in rats with neurogenic bladder hyperactivity [22]. This evidence concerns the gene P2RX3 and urogenital neoplasm.